RETEVMO
- Product NDC
- 0002-6120
- 11-digit product format
- 000026120
- Labeler code
- 0002
- Product ID
- 0002-6120_94e137ac-9f6b-4904-8999-3e55603a2407
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- selpercatinib
- Dosage form
- TABLET, COATED
- Route
- ORAL
- Labeler
- Eli Lilly and Company
- Application
- NDA218160
- Marketing category
- NDA
- Marketing start
- 2024-04-10
- Substance
- SELPERCATINIB
- Active strength
- 120 mg/1
- Pharmacologic classes
- Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Related UNII Ingredients
| UNII | Preferred term | Registry number | Matched term |
|---|
| CEGM9YBNGD | SELPERCATINIB | 2152628-33-4 | SELPERCATINIB |
Packages
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|
| 0002-6120-60 | 00002612060 | 60 TABLET, COATED in 1 BOTTLE (0002-6120-60) | 2024-04-10 | No | No | Historical |
Related DailyMed Labels
| Title | Manufacturer | Effective date | Type | Version |
|---|
| RETEVMO | Eli Lilly and Company | Loxo Oncology, Inc. | 2025-11-20 | HUMAN PRESCRIPTION DRUG LABEL | 22 |